Home > Insider Trading > Filing (0000899243-19-004404)

Filing Details

Accession Number:: 0000899243-19-004404
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-02-21 17:01:11
Reporting Period:: 2019-02-19

Accepted Time:: 2019-02-21 17:01:11
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1750019	Tcr2 Therapeutics Inc.	TCRR	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1575745	Morana Jovan-Embiricos	C/O Tcr2 Therapeutics Inc. 100 Binney Street Cambridge MA 02142	Yes	No	Yes	No
1600769	Ltd Holdings Globeways	3Rd Floor, Geneve Place, Waterfront Dr Po Box 3175, Road Town, Tortola, Bvi Ch-1205 Geneva V8	No	No	Yes	No
1767388	Ltd 2017 Ii Bioscience F2	C/O Lj Partnership, 8, Rue Saint-Leger, Geneva V8 CH-1205	No	No	Yes	No
1767390	Ltd 2017 I Captial F2	C/O Lj Partnership, 8, Rue Saint-Leger, Geneva V8 CH-1205	No	No	Yes	No
1767391	Ltd 2015 I Capital F2	C/O Lj Partnership, 8, Rue Saint-Leger, Geneva V8 CH-1205	No	No	Yes	No
1767396	Ltd Mg F2	C/O Lj Partnership, 8, Rue Saint-Leger, Geneva V8 CH-1205	No	No	Yes	No
1767397	F2 - Tpo Investments Llc	C/O Lj Partnership, 8, Rue Saint-Leger, Geneva V8 CH-1205	No	No	Yes	No
1767415	F2 Bbg Llc	C/O Singer Mckeon Inc, 8 West 38Th St Suite 1001 New York NY 10018	No	No	Yes	No
1767418	F2 Capital I 2019, Llc	C/O Singer Mckeon Inc, 8 West 38Th St Suite 1001 New York NY 10018	No	No	Yes	No
1768161	Ltd Ii Holdings Globeways	3Rd Floor, Geneve Place, Waterfront Dr Po Box 3175, Road Town Tortola, Bvi Ch-1205 Geneva V8	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-02-19	1,614,515	$0.00	1,614,515	No	4	C	Indirect	By Fund
Common Stock	Acquisiton	2019-02-19	193,742	$0.00	193,742	No	4	C	Indirect	By Fund
Common Stock	Acquisiton	2019-02-19	410,168	$0.00	410,168	No	4	C	Indirect	By Fund
Common Stock	Acquisiton	2019-02-19	282,540	$0.00	282,540	No	4	C	Indirect	By Fund
Common Stock	Acquisiton	2019-02-19	403,629	$0.00	403,629	No	4	C	Indirect	By Fund
Common Stock	Acquisiton	2019-02-19	200,000	$15.00	200,000	No	4	P	Indirect	By Fund
Common Stock	Acquisiton	2019-02-19	166,667	$15.00	166,667	No	4	P	Indirect	By Fund
Common Stock	Acquisiton	2019-02-19	166,667	$15.00	449,207	No	4	P	Indirect	By Fund
Common Stock	Acquisiton	2019-02-19	133,333	$15.00	536,962	No	4	P	Indirect	By Fund

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Fund
No	4	C	Indirect	By Fund
No	4	C	Indirect	By Fund
No	4	C	Indirect	By Fund
No	4	C	Indirect	By Fund
No	4	P	Indirect	By Fund
No	4	P	Indirect	By Fund
No	4	P	Indirect	By Fund
No	4	P	Indirect	By Fund

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2019-02-19	10,000,001	$0.00	1,614,515	$0.00
Common Stock	Series B Preferred Stock	Disposition	2019-02-19	1,200,000	$0.00	193,742	$0.00
Common Stock	Series B Preferred Stock	Disposition	2019-02-19	2,540,500	$0.00	410,168	$0.00
Common Stock	Series B Preferred Stock	Disposition	2019-02-19	1,750,000	$0.00	282,540	$0.00
Common Stock	Series B Preferred Stock	Disposition	2019-02-19	2,500,000	$0.00	403,629	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 ("Common Stock"), on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.
The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering..
The reported securities are owned directly by F2 Bioscience II 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Bioscience II 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience II 2017 Limited. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
The reported securities are owned directly F2-TPO Investments, LLC. Globeways Holdings Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
The reported securities are owned directly by F2 BBG LLC. Globeways Holdings II Limited is the appointed manager of F2 BBG LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 BBG LLC. Morana Jovan-Embiricos is the founding director of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.